Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.